在功能性胃肠道疾病中使用埃斯基塔洛普拉姆的可行性和障碍
Saad S Alkhowaiter1, Amani H Alshahrani2, Hala F Almarzouqi2
1Department of Medicine- Gastroenterology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Frontiers in pharmacology
|June 7, 2023
概括
埃斯基塔洛普拉姆是一种安全有效的治疗功能性胃肠道疾病 (FGIDs),包括刺激性肠综合征和功能性胃灼热. 解决患者对精神病药物使用的担忧可以改善治疗的坚持和结果.
科学领域:
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
- 临床药理学 临床药理学
背景情况:
- 在功能性胃肠道疾病 (FGIDs) 中使用埃斯基塔洛普拉姆仍然是有争议的.
- 评估其可行性,安全性,有效性以及沙特人口中的障碍至关重要.
研究的目的:
- 评估ESCITALOPRAM在FGIDs管理中的可行性,安全性和有效性.
- 为了确定沙特人口中使用埃斯基塔洛普拉姆的障碍.
主要方法:
- 一项涉及51名患有FGID (刺激性肠综合征,功能性胃灼热,球体感觉) 的患者的研究.
- 使用刺激性肠综合症严重性评分系统 (IBS-SSS),GerdQ和格拉斯哥爱丁堡喉尺度 (GETS) 进行评估.
- 在埃斯基塔洛普拉姆治疗前后测量疾病严重程度的变化.
主要成果:
- 在治疗后的IBS-SSS (p < 0.001),GerdQ (p = 0.001) 和GETS (p = 0.002) 评分中观察到显著的改善.
- 80.39%的患者经历了轻微的副作用,最常见的是嗜睡/疲劳/头 (54.9%).
- 有35名患者拒绝服用药物,7名患者停止服用药物,这通常是由于对治疗功能障碍的精神药物的恐惧或怀疑.
结论:
- 埃斯基塔洛普拉姆显示出作为FGID安全有效治疗的潜力.
- 通过解决有关精神病药物的担忧来改善患者的遵守是优化治疗结果的关键.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
317
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
317
01:17Drugs for Treatment of Diarrhea-Predominant IBS
219
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
219
01:21Drugs for Treatment of Constipation-Predominant IBS
236
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
236
01:17Assessment of the Gastrointestinal System I: Subjective Data
235
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
235
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
199
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
199
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
120
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
120